Cargando…
Tapentadol extended-release for treatment of chronic pain: a review
Tapentadol is a centrally acting analgesic with a dual mechanism of action of mu receptor agonism and norepinephrine reuptake inhibition. Tapentadol immediate-release is approved by the US Food and Drug Administration for the management of moderate-to-severe acute pain. It was developed to decrease...
Autores principales: | Vadivelu, Nalini, Timchenko, Alexander, Huang, Yili, Sinatra, Raymond |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160834/ https://www.ncbi.nlm.nih.gov/pubmed/21887118 http://dx.doi.org/10.2147/JPR.S14842 |
Ejemplares similares
-
Patient considerations in the use of tapentadol for moderate to severe pain
por: Vadivelu, Nalini, et al.
Publicado: (2013) -
Tapentadol extended release in the management of peripheral diabetic neuropathic pain
por: Vadivelu, Nalini, et al.
Publicado: (2015) -
Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2018) -
Tapentadol extended release for the management of chronic neck pain
por: Billeci, Domenico, et al.
Publicado: (2017) -
Tapentadol Prolonged Release: A Review in Pain Management
por: Deeks, Emma D.
Publicado: (2018)